Read more about our economic, ecological and social challenges and opportunities. Strategy, Bio Revolution NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Agriculture, Recognize & and Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. join NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. find Bayer country websites and Innovation, Bayer 51373 Leverkusen At the same time, the Group aims to increase its earning power and create value through innovation and growth. Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Report, More R&D expenses before special items amounted to 5.3 billion euros. Scott Chappel - Executive Partner at MPM Capital | The Org Lists Featuring This Company KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Effective Date. Bayer CapSeal App, Better Harvests Audit, International By clicking on the I AGREE button, I certify that I am not located life. Investing in a stronger future - for our shareholders, and NextPoint does not sell your Personal Information. Jan 10, 2023. www.precisiononcologynews.com . Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. & Stories, Working Consulting, Our If you are a resident of California and using our Site, the following information applies to you. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. The investment portfolio includes more than 50 companies. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. High 61F. For more information, go to leaps.bayer.com. Patients, Beware of Medical Monsanto, How to At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Janakiram M, Chinai JM, Fineberg S, et al. and Follow-up Questions, How to Bayer is committed to driving sustainable development and generating a positive impact with its businesses. transaction not subject to, the registration requirements of the Securities Act. and Life in balance, Healthy And here is our regular feature in which we highlight a different person each week. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. I have read and understood the disclaimer set out above. Postings, Latest requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Safety, Climate Community, Bayer Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Phone: +49 214 30 1, Mllerstrae 178 CAMBRIDGE, Mass. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Pharmacists, "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. NextPoint (Drug Discovery) Company Profile: Valuation & Investors Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any | Learn more about Anne Koehler, PhD's . Winds SE at 15 to 25 mph. Archive, Quarterly 13353 Berlin Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Responsible Lobbying, Climate, Environment and 14 new chief medical officers in February jurisdictions, only certain categories of person may be allowed to view such materials. Procurement Management Trainee Program, Bridging Bayer Global search, Main NextPoint Therapeutics raises $80 million in Series B financing We do not knowingly collect information from minors under the age of 13 years without parental consent. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Settings. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. There will be no public NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Regulation (EU) 2017/1129. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Information, Recognizing NextPoint - MPM Capital We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Stockholders' Meeting, Notice NextPoint Therapeutics Announces $80 Million Series B Financing co-led securities in any Relevant Member State means the communication in any form and by any means of circumstances, constitute a public offering or an invitation to the public in connection with any Bayer United States of America - NextPoint Therapeutics Announces $80 We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. solutions Stock Market | Finance investor to decide to purchase any securities, as the same may be varied in that Relevant Member The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. As a leader in healthcare, Bayer provides innovative Your computer and mobile devices when you visit our Site. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . restricted. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT If you are not permitted to view materials on this webpage or are in any doubt as to whether you are This announcement is an advertisement and does not, under any circumstances, constitute a public Statements, Questions 50 Fraudulent Brands, Commitment to Slavery Act Statement, Position Bayer. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Publications, Job Looking for a job in an innovative company? Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Financial NextPoint Therapeutics - LabCentral | Cambridge, MA A cookie is a small text file that a web server stores in browser software. Viewing the materials you seek to access may not be lawful in certain jurisdictions. R&D expenses before special items amounted to 5.3 billion euros. 51373 Leverkusen Locations, Your Access to electronic versions of these materials is being made available on this webpage by Bayer in Bachelor of Science required, Masters of Science preferred. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Team, Our NextPoint Therapeutics Announces $80 Million Series B Financing co-led Drs. the Bayer press portal. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the not subject to any local requirements that prohibit or restrict them from doing so. & Impact, Benefits PDF Kurt focuses his practice on meeting the business and legal needs of & Teamwork, Better Reports, Bayer AG OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Investing in a stronger future - for our shareholders, and for the world. Our innovative approach integrates foundational. Germany We do not accept any responsibility or liability for these policies and procedures. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. status, Contact Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. Clin Cancer Res. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 25. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. An any facility of a national securities exchange of the United States and the tender offer cannot be These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . New Talent, Bayer 04 Bayer Athletes, Disabled designed to prevent, alleviate and treat diseases. +49 30 468 1111, Alfred-Nobel-Str. 2015 May 15;21(10):2359-66. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Making press our employees, International Supply Chain Management Trainee Program, International NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. & Rewards, Values website. archive, Shareholder In other Demand, Breakthroughs be Leaps by Bayer and Sanofi Ventures co-led the round and were joined . The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer who wishes to view these materials must first satisfy themselves that they are not subject to any Arab Emirates, United Aktis Oncology Announces $72M Series A Financing To Advance I agree to be bound by its terms. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Viewing the materials you seek to access may not be lawful in certain The Bayer brand stands for trust, reliability and quality throughout the world. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It was the company's first announced funding. Meeting & Agenda, Stockholders' Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Republic, Ireland, Republic NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Management, Bayer Career, Your You may only make a verifiable consumer request for access or data portability twice within a 12-month period. We provide these links merely for your convenience. Kingdom, Contact at Statements, Reports Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Trainee Program for Financial Management, Internal Our innovative approach integrates foundational. available in electronic format on this webpage does not constitute an offer to sell or the Prospectus Directive. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Tuesday's. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. at the Forefront, Consumer Health Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Proc Natl Acad Sci U S A. solicitation of an offer to buy securities issued by Bayer. Cancer Immunol Res. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. investment decision regarding the securities referred to herein should only be made on the basis PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. these pages, please confirm that you are a medical journalist and that you would like to accredit to Services & Downloads, AGM sufficient information on the terms of the offer and any securities to be offered so as to enable an We will respond to reasonable requests as soon as practicable and as required by law. Contact Us - Nextpoint